A case-control study of menopausal estrogen therapy and breast cancer.
A case-control study of menopausal estrogen therapy and breast cancer.
复制标题
DOI：
10.1001/jama.1980.03300420019018
复制
发表时间：
1980-04
期刊：
影响因子：
--
通讯作者：
R. Ross;A. Paganini-Hill;V. Gerkins;T. Mack;R. Pfeffer;M. Arthur;B. Henderson
中科院分区：
文献类型：
--
作者：
R. Ross;A. Paganini-Hill;V. Gerkins;T. Mack;R. Pfeffer;M. Arthur;B. Henderson
在洛杉矶地区的两个退休社区，研究了雌激素替代疗法与女性乳腺癌之间的关系。将138例发生在75岁以下居民的乳腺癌研究病例与年龄和种族匹配的社区对照对象进行了比较。在卵巢完整的女性中，总累积剂量超过1500毫克的风险比估计为2.5。使用各种独立的药物使用信息来源，这种增加是存在的，但在低剂量下是不一致的，在卵巢切除的妇女中检测不到。除了手术证实的良性乳腺疾病病史外，没有重要的混淆来源被识别，也没有风险修饰物被识别。在这些卵巢完好的女性中，与乳房正常的非吸毒者相比，高累积剂量的风险比上升到5.7。
The association between estrogen replacement therapy and female breast cancer was studied in two Los Angeles area retirement communities. The 138 study cases of breast cancer occurring in residents younger than 75 years were compared with age- and race-matched community control subjects. The risk ratio for a total cumulative dose in excess of 1,500 mg was estimated to be 2.5 in women with intact ovaries. This increase was present using various independent sources of drug usage information but was inconsistent at low dose and undetectable in oophorectomized women. No important sources of confounding could be identified, and no risk modifiers could be identified except for a history of surgically confirmed benign breast disease. In such women with intact ovaries, the risk ratio for a high cumulative dose rose to 5.7 relative to nonusers with normal breasts.